Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CTX-009 |
| Synonyms | |
| Therapy Description |
CTX-009 is a bispecific antibody that targets DLL4 and VEGFA, which potentially inhibits tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P02-03). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CTX-009 | CTX009|CTX 009|ES-104|ES104|ES 104|NOV1501|TR 009 | DLL4 Antibody 7 VEGFA Antibody 5 | CTX-009 is a bispecific antibody that targets DLL4 and VEGFA, which potentially inhibits tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P02-03). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05513742 | Phase II | CTX-009 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |